Skip to main content
. 2013 Mar 5;52(6):986–997. doi: 10.1093/rheumatology/ket018

Fig. 3.

Fig. 3

The proportions of patients in the AMPLE study meeting ACR20, -50, and -70 responses over 1 year for the ITT population (n = 318 in the s.c. abatacept group, n = 328 in the adalimumab group). [19]. Copyright © 2013 by the American College of Rheumatology.

AMPLE is an ongoing study comparing s.c. abatacept vs adalimumab in biologic-naïve patients with background MTX. Error bars represent 95% CI.